Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Ozempic and similar drugs are popular with consumers for their weight-loss properties, but a new study suggests they could ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...